Review of Supporting Policies for the Biomedical Industry in Shanghai (Mainland China)

On September 27, 2024, the Shanghai Municipal People’s Government issued the “Several Measures to Accelerate the High Quality Development of the Science and Technology Service Industry in Shanghai” (Hu Fu Ban Gui [2024] No. 14), proposing to further improve the policy system supporting the development of the science and technology service industry, continuously strengthen the function of science and technology innovation sources, promote the construction of the Shanghai International Science and Technology Innovation Center, accelerate the high-quality development of the science and technology service industry, and encourage science and technology service enterprises to focus on industries such as biomedicine, advanced manufacturing, new energy, and new materials.  In addition, on October 10 of the same year, the Management Committee of the Lingang New Area of the China (Shanghai) Pilot Free Trade Zone also issued the revised “Several Measures for the Agglomeration and Development of the Biomedical Industry in the Lingang New Area of the China (Shanghai) Pilot Free Trade Zone”.  This further demonstrates Shanghai’s determination to make biopharmaceuticals one of the three core industries and build a Shanghai International Science and Technology Innovation Center.

Since the release of the 14th Five Year Plan, various relevant units, industrial departments, and parks in Shanghai have issued multiple policies to promote the development of the biopharmaceutical industry.  This article briefly summarizes some important policies and incentives for enterprises or investors references when making new investment decisions.

I. Policy Overview

Overall, the policies that have been released so far are mainly focused on four aspects:

A. Whole picture

This type of policy includes the “14th Five Year Plan” for the development of Shanghai’s biopharmaceutical industry, “Several Opinions of the General Office of the Shanghai Municipal People’s Government on Promoting the High quality Development of the Biopharmaceutical Industry in the City” (the document has now expired), “Action Plan for Promoting the High quality Development of Shanghai’s Biopharmaceutical Industry (2018-2020)”, “Several Policy Measures to Accelerate the Creation of a Global Biopharmaceutical R&D Economy and Industrialization Highland in Shanghai”, “14th Five Year Plan for the Development of Traditional Chinese Medicine in Shanghai”, “14th Five Year Plan for Drug Safety and High quality Development in Shanghai”, “Several Policies to Promote the Development of Shanghai’s Biopharmaceutical Industry (2014 Edition)”，etc.

These policies mainly clarify the basic principles, main objectives, main tasks, and key areas of support for development.  For enterprises and investors, these documents can serve as a reference for formulating strategic goals.  Enterprises can refer to these goals and key areas to measure whether they are on the right path, or to understand which technologies are currently at the forefront or most scarce, and to explore innovative technological points.

B. Encouragement measures for specific sectors

In addition to the whole system design, Shanghai also has some specialized policy support for some sub sectors of the biopharmaceutical industry, such as the “Shanghai Action Plan for Promoting Cell Therapy Technology Innovation and Industrial Development (2022-2024)”, “Shanghai Action Plan for Promoting Gene Therapy Technology Innovation and Industrial Development (2023-2025)”, “Shanghai Action Plan for Accelerating Synthetic Biology Innovation Sources to Build High end Biomanufacturing Industry Clusters (2023-2025)”, “Shanghai Action Plan for Promoting Medical Robot Industry Development (2023-2025)”, “Shanghai Action Plan for Innovative Development of Computational Biology (2023-2025)” and other contents.

These documents mainly provide more detailed incentive measures for specific fields.  If a company belongs to these subsectors, it can seek government funding and support through these documents.

C. Convenient measures for the approval process

Due to the strong regulation of the pharmaceutical industry itself, from the perspective of business flow, it may bring certain obstacles to the business flow of pharmaceutical enterprises.  Therefore, Shanghai has also introduced some institutional convenience measures to optimize approval and regulatory efficiency and minimize obstacles to the development of the industry.  These systems include the “Shanghai Pilot Program for Import of Biomedical Research and Development Items”, “Shanghai Pudong New Area Regulations for Promoting the Construction of Zhangjiang Biomedical Industry to Achieve New Heights”, “2022 Shanghai Biomedical” New and Excellent Drug and Equipment “Product Catalog”, “Shanghai Innovative Medical Device Application Demonstration Project” and other contents.

D. Preferential policies for industrial parks

In order to promote the scale and cluster development of the biopharmaceutical industry and improve the government’s service capabilities, Shanghai has also issued some policies to encourage enterprises to concentrate in specific industrial parks and enjoy more efficient administrative services, such as the “Implementation Plan for Promoting the Characteristic Development of Biopharmaceutical Industrial Parks”, the “Implementation Plan for Innovative Service Mechanisms to Promote the High quality Development of the Medical Device Industry in the City”, the “Shanghai Biopharmaceutical Product Registration Guidance Service Workstation Construction Guidance Plan”, the “Several Measures for Further Improving the Diversified Payment Mechanism to Support the Development of Innovative Pharmaceutical Devices in Shanghai”, and the recently revised “Several Measures for the Agglomeration and Development of the Biopharmaceutical Industry in the Lingang New Area of the China (Shanghai) Pilot Free Trade Zone”, etc.

II. Key focus areas

According to the 14th Five Year Plan for the Development of Strategic Emerging and Leading Industries in Shanghai, the key areas of focus for the development of the biopharmaceutical industry in Shanghai are mainly concentrated in the following three aspects:

1. Innovative drugs and high-end formulations. Focusing on new targets, sites, mechanisms, and molecular entities, Shanghai will focus on developing high-end biological products such as antibody drugs, new vaccines, gene therapy, cell therapy, targeted chemical drugs and new formulations, modern traditional Chinese medicine, etc.
2. High end medical equipment. Shanghai will focus on developing high-end imaging equipment, high-end implant intervention instruments and consumables, surgical treatment and life support equipment, high-end rehabilitation aids, in vitro diagnostic instruments and reagents, biomedical materials, etc.
3. Biotechnology services. Promote preclinical and clinical contract research organization (CRO), contract manufacturing organization/contract development and manufacturing organization (CMO/CDMO) and other services, and promote the integration and application of technologies such as artificial intelligence assisted drug development and digital healthcare solutions.

In the “14th Five Year Plan” for the development of Shanghai’s biopharmaceutical industry, it is refined into six key areas for industrial development:

1. Becoming the core area of the cell therapy industry
2. Become the main birthplace of global innovative drugs for metabolic disorders such as Alzheimer’s disease and diabetes
3. Becoming the main research and development site for innovative traditional Chinese medicine products guided by the application of modern scientific methods in traditional Chinese medicine theory
4. Becoming the first launch site for innovative products of the next generation of high-end medical devices
5. Becoming a gathering place for biotechnology services
6. Becoming a hub for pharmaceutical commercial circulation

Around these key areas, Shanghai has also released a series of action plans, which shows the government’s determination to vigorously develop these fields.

III. Specific incentive measures for each segmented field

A. Innovative drugs

1. Financial subsidies:
a. Innovative drugs: For Class 1 new drugs that have undergone domestic Phase I, II, and III clinical trials and have been produced by applicants registered in Shanghai (theoretically, they can be manufactured in other cities), a maximum of 40% of the R&D investment will be given to each stage according to regulations, with a maximum support of 10 million yuan, 20 million yuan, and 30 million yuan respectively; For Class I cell and gene therapy new drugs that only require early clinical trials and confirmatory clinical trials, support of up to 15 million yuan and 30 million yuan respectively will be given according to regulations. Each unit can receive cumulative financial support to a maximum of 100 million yuan annually. ^[1]

b. Improved drugs: For improved new drugs with high technological content, obvious advantages in safety and effectiveness, obtained by Shanghai registration applicants with drug registration certificates, commissioned to enterprises (including affiliated companies) from other provinces and cities to produce and achieve output, eligible companies will be given funding support of no more than 15% of research and development investment and no more than 7.5 million yuan according to procedures; The cumulative annual support limit for each unit shall not exceed 15 million yuan. ^[2]

c. Innovative headquarters: For enterprises registered in Shanghai that are recognized as innovative headquarters, if their paid in capital and subsequent annual sales revenue reach a certain amount for the first time at the time of registration, the municipal and district governments will provide relevant graded rewards in a lump sum, and the district where they are located will provide rental subsidies. ^[3]

4. R&D headquarters: A research and development center established by a domestic biopharmaceutical enterprise in Shanghai, upgraded to a composite R&D headquarters with integrated functions such as R&D, sales, and settlement. If the added sales and settlement capabilities reach a certain scale, according to the policy of supporting innovative headquarters, one-time graded rewards will be given by the municipal and district governments. ^[4]

2. Supporting measures:
a. Talent introduction: For qualified talents introduced from home and abroad, relevant policy support such as household registration, application for permanent residence permits, and convenient entry and exit will be provided. ^[5]

b. Import and export: Simplify the pre evaluation procedures for key enterprises included in the list of R&D and special goods clearance facilitation. ^[6]

c. Review registration: Promote the implementation of national reform pilot projects, compress the time limit for drug supplement application review to 60 working days, and compress the time limit for drug clinical trial application review and approval to 30 working days; Further research and optimize the application conditions for drug business licenses to provide convenience for centralized sales functions. ^[7]

d. Medical insurance link: Actively recommend innovative drugs to enter the national medical insurance drug catalog. Innovative drugs included will be budgeted separately and will not be included in the hospital’s total medical insurance budget for the current year; For newly added Class 1 innovative drugs that have not yet been included in the national medical insurance drug catalog but whose drug marketing authorization holder is a Shanghai enterprise, as well as innovative medical devices with high clinical use value but not yet included in the medical insurance payment scope, they are encouraged to apply for inclusion in the specific high-value drug protection responsibility scope of “Shanghai Hui Bao” ^[8]

B. Medical devices

1. Financial subsidies
a. For the special review procedures for innovative medical devices entering the national and Shanghai municipal levels, if the Shanghai registration applicant obtains the medical device registration certificate for the first time, and entrusts enterprises (including affiliated companies) from other provinces and cities to produce and realize the output of medical device products., according to the procedures, those who meet the conditions shall be given financial support not exceeding 30% of the research and development investment and a maximum of 5 million yuan; The cumulative annual support limit for each unit shall not exceed 12 million yuan. ^[9]

2. Supporting measures ^[10]
a. Review registration: For Class II medical devices with clear clinical value and strong innovation, it is encouraged to apply for special review procedures, with priority given to registration inspection, technical review, and registration system verification; Medical device products that are the first in the country or meet the priority approval criteria shall be implemented accordingly. The average time limit for the review of Class II medical devices has been compressed to within 40 working days.

b. Related services: Support drug and medical device inspection and testing institutions to strengthen the construction of professional technical service platforms for biological products, implantable medical devices, large medical equipment, and medical software, and provide enterprises with services such as product safety evaluation, quality control, registration and filing, risk assessment, inspection and testing, and technical training.

c. Medical insurance link: Continuously update the “New and Excellent Drug and Device” product catalog, open a “green channel” for innovative drug and device listings, and recommend inclusion in the national medical insurance drug or “Shanghai Hui Bao” catalog for coverage; For the diagnosis and treatment projects related to drugs and innovative medical devices negotiated by the national medical insurance, separate payment will be made in the medical insurance budget and separately paid in the DRG/DIP reform; For high-value innovative medical devices and innovative medical service projects that meet the conditions, they will be independently grouped in DRG/DIP reform, with improved payment standards and no restrictions on the number of high magnification cases; Timely research and include “new and excellent medical equipment” products that meet regulations in the scope of medical insurance payment.

C. Gene therapy

1. Financial subsidies:
a. Patent application fee subsidy: For international invention patents in the field of gene therapy that have been applied for abroad through the PCT pathway and have been granted authorization through relevant patent examination institutions, 50% of the official fees such as registration fees and examination fees will be subsidized, with a maximum of 20,000 yuan per application. Each PCT international application will be supported by no more than 5 countries or regions. ^[11]

b. Financing subsidy: For gene therapy companies that successfully introduce equity financing of RMB 50 million or more (calculated based on the actual amount received), a subsidy of no more than 2% of the actual equity financing amount will be provided, with each company receiving no more than RMB 10 million per year. ^[12]

c. Premium subsidy: Support medical institutions, enterprises, and other entities to purchase liability insurance related to human clinical trials. Eligible entities will receive a 50% financial subsidy on their premiums, with a maximum subsidy of 500,000 yuan per policy. ^[13]

d. Product landing subsidy: For gene therapy products that have undergone clinical trials in China, obtained marketing authorization by Shanghai registered enterprises, and produced in Shanghai, a maximum of 30 million yuan in financial support will be provided, with a cumulative annual support limit of no more than 100 million yuan per unit; ^[14]

2. Supporting system support:
a. Product review: Provide pre – and in progress guidance and services for the registration and application of key gene therapy research products in Shanghai. ^[15]

b. Patent application: Support key enterprises to apply for the Shanghai Intellectual Property Protection Center’s fast pre-approval service filing subject, improve the quality and review speed of patent applications. ^[16]

c. Customs clearance: Promote the pilot work of importing research and development materials in the field of gene therapy, and support relevant enterprises and research and development materials to be included in the “whitelist”; Promote the pilot work of the joint supervision mechanism for the import and export of special items in the field of gene therapy, support key enterprises to apply for pilot units of the joint supervision mechanism, optimize the approval process for key raw materials and supplies related to gene therapy research and production, and accelerate the handling of customs clearance procedures. ^[17]

d. Financial support: Encourage banks in Shanghai to launch more financial service products and support the application of “new drug loans” and other products in the field of gene therapy; Deepen the “Pujiang Light” campaign and support gene therapy related enterprises to list on domestic and foreign capital markets such as the Science and Technology Innovation Board; Strengthen the listing services of securities firms and other financial institutions for high-quality gene therapy companies; Promote excellent gene therapy companies and other technology enterprises listed overseas to return to the Shanghai Stock Exchange’s Science and Technology Innovation Board for listing. ^[18]

e. Application support: Actively recommend eligible innovative gene therapy products to enter the national medical insurance drug catalog, and explore diversified payment methods; Support the inclusion of gene therapy drugs for rare diseases and other fields in the scope of commercial medical insurance such as “Shanghai Huibao” that benefits the people; Give full play to the role of multi-level commercial medical insurance, and promote Shanghai enterprises, commercial insurance companies, and medical institutions to explore innovative payment models such as installment payments and payment based on treatment efficacy. ^[19]

f. Talent cultivation: Recommend key units in the field of gene therapy to be included in the list of key institutions for talent introduction; Increase support for gene therapy related talents from special projects such as Qimingxing, academic/technical leaders, and industry elites; Pilot the establishment of engineering master’s and doctoral training programs in the field of gene therapy, and explore a new model of resident training for engineering master’s and doctoral students in enterprises; Encourage enterprises and institutions in the field of gene therapy to establish postdoctoral research workstations or settle in postdoctoral innovation practice bases, and support postdoctoral personnel to apply for Shanghai’s “Super Postdoctoral” projects. ^[20]

D. Cell therapy

1. Financial subsidies:
a. Product landing subsidy: Strengthen the support for the launch of innovative products by Shanghai enterprises, and provide up to 30 million yuan in financial support for cell therapy products registered in Shanghai, approved for listing, and transformed in Shanghai. The cumulative annual support amount for each unit shall not exceed 100 million yuan. ^[21]

b. Premium subsidy: Support cell therapy related enterprises to purchase biopharmaceutical product liability insurance, and provide a 50% financial subsidy for eligible entities’ premiums. The subsidy for a single policy shall not exceed 500,000 yuan. ^[22]

2. Supporting system:
a. Product review: Provide pre – and mid process guidance and services for product review and approval for key varieties that require priority communication and exchange, and accelerate the process of launching cell therapy products. ^[23]

b. Customs Import: Promote the pilot work of importing research and development materials, establish a joint supervision mechanism for the import and export of special cell therapy materials, and optimize the management procedures for the import and export of high-risk treatment materials. Research and optimize inspection measures for situations where X-ray examination may damage blood cell activity. ^[24]

c. Ethical review: Explore and promote mutual recognition of ethics among hospitals, improve the efficiency and quality of ethical review, and protect the safety, health, and rights of subjects. ^[25]

d. Application and promotion: Actively recommend innovative cell therapy products that have already been listed to enter the national medical insurance drug catalog and commercial medical insurance programs such as “Shanghai Huibao” that benefit the people; Promote cooperation among enterprises, commercial insurance companies, and medical institutions in Shanghai to explore innovative payment models such as installment payments and payment based on treatment efficacy; Encourage research institutions, medical institutions, and enterprises related to cell therapy to purchase liability insurance products related to human clinical trials; Encourage hospitals to prioritize the use of cell therapy products developed and produced in Shanghai under equal conditions; Cell therapy drugs that are currently undergoing clinical trials for the treatment of serious life-threatening diseases for which there is currently no effective treatment method, may benefit from medical observation and comply with ethical principles. After review and informed consent, they can be used in institutions conducting clinical trials for other patients with the same condition. ^[26]

e. Talent cultivation: Implement the evaluation project for high-end technical talents in the cell therapy industry and vigorously introduce high-end talents. Actively recommend key units in the field of cell therapy to be included in the list of key talent introduction institutions, support qualified overseas talents with cell therapy related work experience to apply for settlement in accordance with the settlement policy for returned overseas students, and enjoy preferential policies such as children’s education^{. [27]}

f. Financial support: Give full play to the guiding role of government investment funds such as Shanghai Biomedical Industry Equity Investment Fund, and increase support for start-up and growth stage cell therapy enterprises. Intensify credit allocation to cell therapy enterprises, encourage the launch of more financial service products in Shanghai banks, and support the application of “new drug loans” and other products in the field of cell therapy. Deepen the “Pujiang Light” campaign, promote the listing of cell therapy related enterprises on domestic and foreign capital markets such as the Science and Technology Innovation Board, and provide support and rewards.  Strengthen the listing services of securities firms and other financial institutions for high-quality cell therapy companies.  Encourage and guide social capital to gather and invest in the field of cell therapy, support mergers and acquisitions, accelerate industrial upgrading, and expand and strengthen innovative enterprises. ^[28]

E. Medical robots

1. Financial subsidies:
According to the “Action Plan for Promoting the Development of the Medical Robot Industry in Shanghai (2023-2025)”, there are no specific subsidies for medical robots.  However, for projects involving core technology research, heavyweight product development, product launch, first set, and post launch re-evaluation in the field of medical robots, funding support can be applied for through “Strategic Emerging Industries”, “Promoting High quality Industrial Development”, “Science and Technology Innovation Action Plan”, “Zhangjiang Independent Innovation Demonstration Zone Development” and other projects. [29]

2. Supporting system:
In addition to funding subsidies, the Shanghai Municipal Government has also proposed to increase support in the evaluation and approval of medical robots, government procurement of innovative products, inclusion in medical insurance payments, acceleration of hospitalization, application demonstrations, and hospital assessment and evaluation. For talent introduction, preferential measures such as the Magnolia Talent Plan and the Oriental Talent Plan can be applied. ^[30]

F. Computational biology

Shanghai has established a “Computational Biology” special project in the Science and Technology Innovation Action Plan of the Municipal Science and Technology Commission for Computational Biology.  Each year, funding will be provided based on the specific project approval situation (ranging from 2 to 3 million yuan per project, with specific reference to the annual project approval notice).  In addition, support measures such as building a Shanghai biological big data platform, establishing key laboratories, building new research and development institutions, establishing an “innovation alliance” for computational biology, and strengthening talent introduction have also been proposed. ^[31]

G. Biotechnology services

According to the “Several Measures to Accelerate the High Quality Development of Science and Technology Service Industry in Shanghai”, science and technology service industry enterprises are encouraged to implement major innovation projects with high technological content and strong demonstration and driving effects.  Those that meet the conditions will be included in the special funds for the development of Shanghai’s service industry in accordance with regulations for support.  Technology service industry enterprises are encouraged to build innovative corporate headquarters, regional headquarters of multinational corporations, and headquarters of private enterprises, and introduce high-end service industry projects.  Those who meet the conditions will be included in special policies such as enterprise headquarters recognition and rewards, modern industrial system measures, etc. in accordance with regulations for support.  Support technology service industry enterprises to establish enterprise laboratories, technology innovation centers, professional technical service platforms, foreign-funded R&D centers, open innovation centers, innovation consortia, etc., and provide support in accordance with relevant regulations; Encourage technology service industry enterprises to be included in the “Pujiang Light” digital service platform.

Therefore, biotechnology service enterprises that meet the conditions can also enjoy the above preferential measures.  In addition, they can also enjoy favorable measures such as enterprise land use, affordable rental housing, and talent settlement.

In addition, for major investment projects newly added by technology service industry enterprises, support will be given of up to 10% of the total investment amount of the total investment amount and a maximum of 5 million yuan; For technology service industry enterprises that meet the standards for the first time, a financial reward of no more than 200,000 yuan will be given at the municipal level; For technology service industry enterprises with high year-on-year growth, a financial reward of no more than 100,000 yuan will be given at the municipal level.

IV. Matters needing attention

The various incentive policies mentioned in this article are not exhaustive, but rather a summary of the more important or particularly applicable measures for the biopharmaceutical industry.  If enterprises are planning to invest, they can consult the industrial park.  It is particularly important to note that there are significant subsidies and preferential policies for major technological breakthroughs, clinical trials, clinical research, obtaining FDA and other professional qualification /certifications, obtaining production approvals and marketing licenses, commissioned production and sales, key raw material procurement, expanding overseas markets, investing in professional technical service platforms, and digital medical demonstrations related to the biopharmaceutical industry in the Lingang area.  ^[32] Enterprises can also consult relevant departments of the Lingang Management Committee in detail if needed.

In addition to these specific support policies for the biopharmaceutical industry, Shanghai also has specific support policies for technology innovation industries, major projects, etc.  Even biopharmaceutical companies that meet the conditions can apply to enjoy them.  But generally speaking, if there are overlapping preferential policies, they are only allowed to be enjoyed according to the principle of “great priority, high priority, and non duplication”, and the scope of application is only applicable to enterprises, institutions, or private non enterprise units registered in Shanghai engaged in research and development, production, and professional services in the fields of drugs, medical devices, biotechnology, and life science research instruments. ^[33]

[1] Refer to Article 1 of the “Several Opinions of the General Office of the Shanghai Municipal People’s Government on Supporting the Innovative Development of the Whole Chain of the Biomedical Industry”
[2] Refer to Article 3 of the “Several Policy Measures for Shanghai to Accelerate the Construction of a Global Biomedical R&D Economy and Industrialization Highland”
[3] Refer to Article 4 of the “Several Policy Measures for Shanghai to Accelerate the Construction of a Global Biomedical R&D Economy and Industrialization Highland”
[4] Refer to Article 4 of the “Several Policy Measures for Shanghai to Accelerate the Construction of a Global Biomedical R&D Economy and Industrialization Highland”
[5] Refer to Article 4 of the “Several Policy Measures for Shanghai to Accelerate the Construction of a Global Biomedical R&D Economy and Industrialization Highland”
[6] Refer to Article 4 of the “Several Policy Measures for Shanghai to Accelerate the Construction of a Global Biomedical R&D Economy and Industrialization Highland”
[7] Refer to Article 3 of the “Several Opinions of the General Office of the Shanghai Municipal People’s Government on Supporting the Innovative Development of the Whole Chain of the Biomedical Industry”
[8] Refer to Article 7 of the “Several Policy Measures for Shanghai to Accelerate the Construction of a Global Biomedical R&D Economy and Industrialization Highland”
[9] Refer to Article 3 of the “Several Policy Measures for Shanghai to Accelerate the Construction of a Global Biomedical R&D Economy and Industrialization Highland”
[10] Refer to Articles 3 and 4 of the “Several Opinions of the General Office of the Shanghai Municipal People’s Government on Supporting the Innovative Development of the Whole Chain of the Biomedical Industry”
[11] Refer to Article 5 (3) of the Action Plan for Promoting Gene Therapy Technology Innovation and Industrial Development in Shanghai (2023-2025)
[12] Refer to Article 5 (6) of the Action Plan for Promoting Gene Therapy Technology Innovation and Industrial Development in Shanghai (2023-2025)
[13] Refer to Article 5 (5) of the Action Plan for Promoting Gene Therapy Technology Innovation and Industrial Development in Shanghai (2023-2025)
[14] Refer to Article 5 (4) of the Action Plan for Promoting Gene Therapy Technology Innovation and Industrial Development in Shanghai (2023-2025)
[15] Refer to Article 5 (2) of the Action Plan for Promoting Gene Therapy Technology Innovation and Industrial Development in Shanghai (2023-2025)
[16] Refer to Article 5 (3) of the Action Plan for Promoting Gene Therapy Technology Innovation and Industrial Development in Shanghai (2023-2025)
[17] Refer to Article 5 (8) of the Action Plan for Promoting Gene Therapy Technology Innovation and Industrial Development in Shanghai (2023-2025)
[18] Refer to Article 5 (6) of the Action Plan for Promoting Gene Therapy Technology Innovation and Industrial Development in Shanghai (2023-2025)
[19] Refer to Article 5 (5) of the Action Plan for Promoting Gene Therapy Technology Innovation and Industrial Development in Shanghai (2023-2025)
[20] Refer to Article 5 (7) of the Action Plan for Promoting Gene Therapy Technology Innovation and Industrial Development in Shanghai (2023-2025)
[21] Refer to Article 4 (4) 11 of the Action Plan for Promoting Technological Innovation and Industrial Development of Cell Therapy in Shanghai (2022-2024)
[22] Refer to Article 4 (4) 11 of the Action Plan for Promoting Technological Innovation and Industrial Development of Cell Therapy in Shanghai (2022-2024)
[23] Refer to Article 4 (4) 11 of the Action Plan for Promoting Technological Innovation and Industrial Development of Cell Therapy in Shanghai (2022-2024)
[24] Refer to Article 4 (4) 12 of the Action Plan for Promoting Technological Innovation and Industrial Development of Cell Therapy in Shanghai (2022-2024)
[25] Refer to Article 4 (4) 13 of the Action Plan for Promoting Technological Innovation and Industrial Development of Cell Therapy in Shanghai (2022-2024)
[26] Refer to Article 5 (1) of the Action Plan for Promoting Technological Innovation and Industrial Development of Cell Therapy in Shanghai (2022-2024)
[27] Refer to Article 5 (2) of the Action Plan for Promoting Technological Innovation and Industrial Development of Cell Therapy in Shanghai (2022-2024)
[28] Refer to Article 5 (3) of the Action Plan for Promoting Technological Innovation and Industrial Development of Cell Therapy in Shanghai (2022-2024)
[29] Refer to Article 4.2 of the Action Plan for Promoting the Development of the Medical Robot Industry in Shanghai (2023-2025)
[30] Refer to Article 4.3 of the Action Plan for Promoting the Development of the Medical Robot Industry in Shanghai (2023-2025)
[31] Refer to the Action Plan for Innovative Development of Computational Biology in Shanghai (2023-2025).
[32] Refer to the “Several Measures for the Agglomeration and Development of Biomedical Industry in Lingang New Area of China (Shanghai) Pilot Free Trade Zone” (2024 revised version).
[33] Refer to the “Several Opinions of the General Office of the Shanghai Municipal People’s Government on Supporting the Innovative Development of the Whole Chain of the Biomedical Industry”.